SEC Filing Summary: Pro-Pharmaceuticals, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pro-Pharmaceuticals, Inc. on January 16, 2007. The report discloses a corporate governance event regarding the Board of Directors. Note: The request metadata references "GALECTIN THERAPEUTICS INC," but the filing text explicitly identifies the registrant as "PRO-PHARMACEUTICALS, INC."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a disclosure of personnel changes and does not contain financial statements or performance data.
Material Changes
On January 16, 2007, the company received notification of the resignation of Burton C. Firtel from the Board of Directors. The resignation is effective immediately.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies related to the resignation are detailed in the text, other than the immediate departure of the director.
Key Facts for Investor Verification
- Confirm the identity of the registrant (Pro-Pharmaceuticals, Inc.) versus the metadata reference (Galectin Therapeutics Inc).
- Verify the effective date of Burton C. Firtel's resignation (January 16, 2007).
- Review the attached resignation letter (Exhibit 17.1) for any stated reasons for departure.
- Check subsequent filings to determine if a replacement director was appointed.